Group on Medicinal Product Risk Communication (ISoP CommSIG)Pharmacovigilance has developed, and continues to develop, a wealth of surveillance methods, pharmacological knowledge, and measures for preventing patient harm.However, ensuring the safe use of medicines in daily healthcare remains a challenge and requires strong collaboration across medicines regulatory bodies, pharmaceutical companies, healthcare professionals, health policy makers, and patients.Many patients today expect a dialogue with their healthcare professionals and participation in decisions regarding their treatment.Communication may at times be challenging for pharmacovigilance specialists who are first of all dedicated to the collection and assessment of data on adverse events.Recognising the importance of communication, the International Society of Pharmacovigilance (ISoP) launched a Special Interest Group on Medicinal Product